Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a malignancy occurring after exposure to chemotherapy and/or radiotherapy. Polymorphisms involved in chemotherapy/radiotherapy response genes could be related to an increased risk of developing this neoplasia. We have studied 11 polymorphisms in genes of drug detoxification pathways (NQO1, glutathione S-transferase pi) and DNA repair xeroderma pigmentosum, complementation group (3) (XPC(3), X-ray repair cross complementing protein (1)), Nijmegen breakage syndrome (1), excision repair cross-complementing rodent repair deficiency, complementation group (5) and X-ray repair cross complementing protein (3) and in the methylene tetrahydrofolate reductase gene (MTHFR(2), 677C4T, 1298A4C), involved in DNA synthesis. The analyzed groups were a t-MDS/ AML patients group (n ¼ 81) and a matched control group (n ¼ 64) treated similarly, and they did not develop t-MDS/AML. We found no significant differences when the groups were compared globally. However, when analysis was carried out according to the primary neoplasia involved, a significant association was observed between the MTHFR haplotype (single nucleotide polymorphisms 677 and 1298) and the risk of developing t-MDS/AML in the breast cancer patients group (P ¼ 0.016) and cyclophosphamide-treated hematological disease group (P ¼ 0.005). Risk haplotype was different for each case, corresponding to the 677T1298A haplotype after breast cancer treatment and the 677C1298C haplotype after hematological malignancy treatment. We postulate that such differences are related to variations in chemotherapy schemes between hematological and breast cancers and their differential interaction with the MTHFR route.
Introduction
Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a well-recognized clinical syndrome occurring as a late complication after cytotoxic therapy. 1 It constitutes the most frequent secondary neoplasia, and its incidence has increased over the last few years. Alternative genetic pathways recently have been reviewed in the pathogenesis of illness based on chromosome aberrations and mutations of genes of importance for hematopoiesis. 2 Several studies have addressed cumulative dose, dose intensity and exposure to specific agents of preceding cytotoxic therapy in relation to the risk of developing such leukemia. 1 Typical chemotherapeutic agents related to secondary leukemias include alkylating agents and topoisomerase II inhibitors. 3 However, some cases of secondary leukemias have been reported after exposure to chemotherapy based on other chemotherapeutic drugs, for example antimetabolites such as 5-fluorouracil (5-FU) 4 -though these agents are rarely administered alone and tend to be combined with several other drugs. Since only a small percentage of patients exposed to cytotoxic therapy develop t-MDS/AML, it has been suggested that some genetic predisposition may be involved, specifically associated to polymorphisms in certain genes involved in chemotherapy/radiotherapy response, 5 such as genes involved in DNA repair, 6 oxidative stress 7 and drug detoxification. 8 Considering that several chemotherapeutic agents induce DNA damage, a minor DNA repair capability could originate an increase of DNA aberrations that can originate secondary leukemias. Many single nucleotide polymorphisms (SNPs) have been implicated in the mechanisms of DNA repair. 9 Some of them involve changes in the protein sequence, with a relative abundance of infrequent alleles (greater than 20%) in the general population and located in the X-ray repair cross complementing protein (1) (XRCC1), X-ray repair cross complementing protein (3) (XRCC3), Nijmegen breakage syndrome (1) (NBS1), excision repair cross-complementing rodent repair deficiency, complementation group (5) (ERCC5) and xeroderma pigmentosum, complementation group (c) (XPC) genes. 9 XRCC1 encodes for an enzyme implicated in the repair of breakage of the simple-DNA strand via a base excision mechanism. XRCC3 and NBS1 in turn encode for enzymes involved in the repair of double-strand DNA breakage, whereas the ERCC5 and XPC genes encode for proteins that take part in DNA repair via a nucleotide excision mechanism. 9 XRCC1 plays a key role in gene repair and is required for genomic stability in human cells. 10 Several variants of XRCC1 have been described, including one affecting codon 399 in exon 10 that results in an arginine (Arg) to glutamine (Gln) substitution, which has been associated with an increase in the risk of developing t-MDS/AML. 6 Among the oxidative stress genes, those encoding for the glutathione S-transferases (GTS) are the most widely studied in relation to their influence upon treatment-related toxicity. GTS are enzymes that mediate conjugation of electrophilic compounds to glutathione, resulting in detoxification of some chemotherapeutic drugs -including alkylating agents, doxorubicin and vincristine. 11 Some reports indicate a potential role for GST polymorphisms in the etiology of treatment related toxicity, presumably due to impaired detoxification of chemotherapy agents. 7, [12] [13] [14] Specifically, inheritance of the GSTP1 (glutathione S-transferase pi) valine allele in codon 105 is associated with an increased risk of treatment related leukemia, particularly in those patients who have been treated with chemotherapeutic drugs that are substrates of GSTP1. 7 In reference to drug detoxification genes, NAD(P)H dehydrogenase Quinone 1 gene (NQO1) is the most widely studied in relation to its influence upon t-MDS/AML. NQO1 catalyzes the reduction of quinines, quinone amines and azo compounds, which can be overproduced after chemotherapy, thereby interfering with their participation in redox cycling and the generation of reactive-oxygen species that may go on to damage DNA. A polymorphism of this gene, located in codon 187, has been associated with an increased risk of t-MDS/AML in patients induced by alkylating agents. 15 Interaction between genes and chemotherapy exposure is being extensively studied for SNPs in the methylene tetrahydrofolate reductase (MTHFR) gene. MTHFR directs 5,10-methylene tetrahydrofolate toward methionine synthesis at the expense of dUMP synthesis, required for DNA synthesis and repair. Two MTHFR polymorphisms, C677T and A1298C, have been associated with reduced enzyme activity, and C677T has been related to altered distribution of intracellular folate metabolites. 16 Folate deficiency has been associated with uracil misincorporation into DNA and DNA double-strand ruptures during uracil excision repair -thus increasing the risk of chromosomal aberrations. 16 Since some antimetabolite agents, such as methotrexate, 5-FU, cytarabine and others, produce metabolites that interact with metabolic routes in which MTHFR is involved, the influence of the different allele variants in relation to patient response to treatment with these drugs is being extensively studied. 17, 18 In order to determine gene influence in the development of t-MDS/AML, we have studied 11 polymorphisms located in genes relating to drug detoxification pathways (NQO1, GSTP1), DNA repair (XPC(3), XRCC1(1), NBS1, ERCC5 and XRCC3 and DNA synthesis (MTHFR 677 and 1298), with an abundance of infrequent alleles (greater than 20%) in the general population, in which the nucleotide change implies a change in protein sequence (see Table 3 for details). Thus, if an association between SNP and disease is found, the influence of such SNPs upon the disease could be explained as a result of modifications in protein function due to amino-acid substitution. The exception is an SNP located in intron 11 of the XPC gene, which we have included in our study because it has been related to a change in XPC mRNA splicing 19 that could have functional consequences as important as aminoacid substitution.
Materials and methods

Study subjects
Blood or bone marrow samples were obtained from healthy individuals and patients who were enrolled and treated in eight Spanish institutions (Valencia University Clinic Hospital, Navarra University Clinic, Barcelona Clinic Hospital, Salamanca University Clinic, Central University Hospital of Asturias, Sant Pau Hospital in Barcelona, La Fe Hospital in Valencia) after informed consent (according to the Declaration of Helsinki) was obtained. Local IRB approval for this study was obtained from the Ethics Committee of Valencia University Clinic Hospital.
The t-MDS/AML group was composed of patients in whom, the primary malignancy was hematological in 44 cases (18 subjected to autologous stem cell transplantation (ASCT)), breast cancer in 17 cases and other causes in 20 cases (these 20 cases were not matched in the control group and were not included in the t-AML vs control genotype analysis). t-MDS/AML diagnosis was made in the center of origin according to FrenchAmerican-British or (World Health Organization) criteria. 20 The control group was defined as patients with hematological or breast cancer as primary disease treated for a primary neoplasia with chemo-or radiotherapy schemes, similar to those applied to patients with t-MDS/AML, and who 7 years or more after treatment did not develop a secondary malignancy. Emphasis was placed on matching chemotherapy schemes in terms of exposure to alkylating and topoisomerase II inhibitors, and dose intensity (whether myeloablative chemotherapy for ASCT was provided or not). The control group was composed of 46 patients with hematological malignancies (17 with ASCT) and 18 patients with breast cancer. Tables 1, 2 and 3 summarize the characteristics of the different groups (primary disease, age of primary and second disease and treatments).
We also analyzed a group of 80 healthy individuals residing in the same geographical setting, and recruited from among regular blood donors in a different time period and context from the rest of the individuals, to ensure that they were not related to the patients.
Although samples were not matched for sex and age, differences in median age between control and case groups were not allowed to reach more than 10 years in any case. With respect with sex, previous investigations consistently found no significant difference between male and female subjects in the distribution of some genotypes investigated in this study. 21, 22 Additionally, we confirmed that there were no differences associated to sex in any of the SNPs studied, by confronting the genotypes of 40 male subjects vs 40 female subjects in the healthy donor group (data not shown).
Genotyping
Genomic DNA was extracted from cells by using the DNeasy tissue kit from Qiagen (Izasa, Madrid, Spain) according to manufacturer protocol. Genotyping analysis of the 11 SNPs was performed by polymerase chain reaction (PCR)-restriction fragment-length polymorphism. PCR conditions were standard except for annealing temperature, which was specific for each fragment (see Table 4 for details). Briefly, PCR mixture contained 25 ng of genomic DNA, 1 mM of each primer 
Statistical analysis
The general statistical study (median age) was made using the SPSS statistical package for Microsoft Windows. The specific statistical tools for genotype analysis of SNPs (Hardy-Weinberg equilibrium, allele and genotype distributions and association test) were provided by SNPStats, a web tool for SNP analysis developed by the Catalan Institute of Oncology. 23 P-values of less than or equal to 0.05 were considered to represent statistical significance. Linkage disequilibrium and haplotype association analysis for SNPs in the same gene were performed using the Haplostats statistical package 24 from R project for Statistical Computing (www.r-project.org/).
Results
Genotyping analysis
We examined the frequency of 11 polymorphisms in 81 patients with t-MDS/AML, 64 controls and 80 healthy donors. All genotype frequencies were consistent with those expected from the Hardy-Weinberg equilibrium. Results of single-SNP association test for these groups are shown in Table 5 . Comparison of polymorphisms between the control group and t-MDS/AML was made excluding 20 cases, which could not be matched in the control group by primary disease (t-MDS/AML 1 ). No significant differences were observed between the t-MDS/AML groups (t-MDS/AML and t-MDS/AML 1 ) and the non t-MDS/AML groups (healthy donors and controls), respectively (see Table 5 ). However, on distributing the individuals according to primary disease (breast cancer and hematological cancer) and, where possible, according to chemotherapy scheme and dose intensity (ASCT or no ASCT treatment, in the case of hematological patients), we found statistically significant differences in genotypes of MTHFR.
Both SNPs of the MTHFR gene (677,1298) showed significant differences between cases and controls when patients belonged to the subpopulation with breast cancer as primary disease. For SNP C677T, the greatest significance was achieved for a dominant model where T-mutant alleles in homozygosis or heterozygosis (TT/CT) had an increased risk of developing t-MDS/AML referred to the CC homozygotic wild type (P ¼ 0.0008, odds ratio (OR) ¼ 20.00, 95% CI (2.16-184.81). For SNP A1298C, homozygotic wild-type AA had an increased risk of developing t-MDS/AML referred to the rest of genotypes AC/CC (P ¼ 0.0091, OR ¼ 6.50, 95% CI (1.47-28.80)). Additionally, we carried out genotype analysis, considering only breast cancer patients who received chemotherapy schemes, which included 5-FU as adjuvant chemotherapy. The results were very similar, though the values were slightly less significant (for SNP C677T P ¼ 0.0034, OR ¼ 15.71, 95% CI ¼ (1.63-151.07) and for SNP 1298 P ¼ 0.032, OR ¼ 5.5, 95% CI ¼ (1.06-28.42)) -due to a loss of number of individuals in the case group (from 17 to 12). For the hematological population, a slightly significant difference was observed for MTHFR A1298C SNP (but not for C677T). In this case the risk Table 3 for details) were considered for genotype analysis (P ¼ 0.0016, OR ¼ 11.37, 95% CI ¼ 2.04-60.28). Since MTHFR 677 and 1298 are located in the same gene, we calculated the linkage disequilibrium for this pair. We found these SNPs to be fully linked (D 0 statistic 0.9991 for hematological and 0.9993 for breast cancer subjects), and then performed haplotype association analysis for this pair of SNPs in each subpopulation (see results in Table 6 for breast cancer and in Table 7 for the non-ASCT hematological subpopulation). Statistical analysis displayed a frequency of 0% for double-mutant T(677)C(1298) haplotype (TC) in both subpopulations, which agrees with data from previous reports indicating that double-mutant haplotypes are an infrequent event. 25 Thus, only three haplotypes were considered for analysis: wild-type C(677)A(1298) haplotype (abbrev CA); T(677)A(1298) haplotype, which is a variant with the single mutation in the 677 position (TA); and C(677)C(1298) haplotype, which is a variant with a single mutation in the 1298 position (CC). As three haplotypes (CA, TA and CC) are quite abundant in the general population, and wild-type CA is not the most frequent haplotype (estimated frequencies in healthy donor group for each haplotype are CA ¼ 26.47%, CC ¼ 31.03% and TA ¼ 41.65%), we have used as base haplotype for OR calculations not only wild-type CA, but also TA and CC.
For the breast cancer subpopulation (Table 6a) , we found differences in haplotype frequencies between cases and controls to be statistically significant for TA (P ¼ 0.0045) and CC haplotypes (P ¼ 0.020) -TA haplotype being more frequent in cases (61%) than in controls (27%), while CC was more frequent in controls (41%) than in cases (14%). Haplotype analysis displayed an OR for TA referred to wild-type CA (OR TA/CA ) of 3.91 (P ¼ 0.09), and referred to CC (OR TA/CC ) of 5.98 (P ¼ 0.013)(global P association ¼ 0.016). When only breast cancer 5-FU-treated patients were considered (Table 6b) , the values were OR TA/CA ¼ 4.35 (P ¼ 0.088) and OR TA/CC ¼ 4.55 (P ¼ 0.032)(global P-haplotype association ¼ 0.038). These data suggest TA to be a risk haplotype for developing t-MDS/AML after treatment for breast cancer.
For the non-transplanted hematological subpopulation (Table 7a) , we found haplotype frequency differences between cases and controls that were statistically significant for CC haplotype (P ¼ 0.0042) -this haplotype being more frequent in cases (46.6%) than in controls (18.2%). Haplotype analysis displayed an OR for CC referred to wild-type CA (OR CC/CA ) of 4.71(P ¼ 0.0092), and referred to TA (OR CC/TA ) of 4.81 (P ¼ 0.0129) (global P association value ¼ 0.016). When only cyclophosphamide scheme treated patients were considered (Table 7b) , OR and statistical significance were seen to increase (OR CC/CA ¼ 16.28 (P ¼ 0.0017) and OR CC/TA ¼ 7.74 (P ¼ 0.0236) (global P-association value ¼ 0.005). These data suggest CC to be a risk haplotype for t-MDS/AML after primary hematological malignancies treated with cyclophosphamide-based schemes.
Discussion
Determination of certain genetic influences upon the development of secondary leukemia is not a simple issue, primarily MTHFR haplotype role in secondary leukemia VM Guillem et al because of the heterogeneity of treatments, which makes it difficult to analyze the genetic predisposition associated to each drug or radiation. Thus, comparison should be made between groups that receive treatments that are as homogeneous as possible, in order to prevent several uncontrolled factors from influencing the results. Accordingly, we defined our control group as patients with similar primary disease who received treatment similar to that of the secondary leukemia patients, and who 7 years or more after treatment did not develop a secondary malignancy. Emphasis was placed on matching chemotherapy schemes in terms of exposure to alkylating and topoisomerase II inhibitors, and dose intensity, which are the main risk factors for developing secondary leukemia. We distributed patients into two groups: patients with hematological malignancies, where secondary leukemia is relatively frequent, and breast cancer patients. This is because while infrequent (less than 1%), several cases of t-MDS/AML after breast cancer therapy are diagnosed each year. Among the hematological cases, we took into account whether or not the patients had received myeloablative chemotherapy, and which kind of chemotherapy schemes they received. We found no statistically significant differences between the t-MDS/AML and control groups when the data were analyzed globally. However, when analysis was made according to the primary disease involved, we found statistically significant differences in MTHFR SNPs. In the breast cancer group, differences between the t-MDS/AML and control groups were statistically significant for both 677 and 1298 SNPs, while in the case of the hematological malignancies only the MHFTR 1298 genotype proved relevant (P ¼ 0.042 OR ¼ 2.39). Since the hematological subpopulation was more heterogeneous, in terms of primary disease and treatment, compared with the breast cancer subpopulation, we wanted to know whether this genetic trait was general for all hematological patients or specific for certain types of treatment. Thus, we separately analyzed the genotype distribution in hematological patients who received myeloablative chemotherapy and those who did not. We found that differences were exclusively limited to the non-myeloablative chemotherapy group (P ¼ 0.0053, OR ¼ 4.8), while no association was found in the myeloablative chemotherapy group (P ¼ 0.86, OR ¼ 0.89). Although relevance of the MTHFR 1298 genotype after myeloablative chemotherapy could not be discarded due to the small size of the study population (n ¼ 35), other potential influencing factors could explain such differences -such as dose intensity and the chemotherapeutic drugs used (such patients receive high doses of alkylating carmustine, which was not received by non-ASCT patients at all). Moreover, we aimed to define which treatment in particular was related to the genotype differences. We considered for additional analysis only cyclophosphamide-based schemes, because of their additional homogeneity: these schemes generally include other chemotherapeutic drugs such as antitumor antibiotics, antimetabolites and vinca alkaloids. We found that the differences became greater and OR increased -thus suggesting that MTHFR influence upon t-MDS/AML risk is associated with such treatment. Surprisingly, MTHFR risk genotype/haplotype proved different for each subpopulation. For the breast cancer population, genotype analysis yielded the best match for SNP 677 in a dominant model, where TT/CT genotypes have increased risk with respect to the CC genotype, while no association with this SNP was found for hematological populations in any case. For SNP 1298 in the breast cancer population, the best match was found for a recessive model, where homozygous AA showed increased risk with respect to the CC/AC genotype, while in the case of the hematological populations the best match was found for a dominant model, where CC/AC genotypes showed an increased risk of t-MDS/AML referred to AA genotypes. To interpret such apparently contradictory findings, we must take several considerations into account. Firstly, such SNPs are located in the same gene and are presumed to be MTHFR haplotype role in secondary leukemia VM Guillem et al linked to some degree; as a result, they must be analyzed together, not separately. This implies haplotype analysis. Secondly, chemotherapy schemes for breast cancer and hematological malignancies have some critical differences, specifically those referring to the kind of drugs used. Some of these drugs directly interact with MTHFR pathways. Understanding how each drug interacts with each MTHFR genotype/ haplotype is critical to find an explanation to our results, as will be seen below.
Description of MTHFR haplotypes and their biological differences
The two MTHFR polymorphisms 677 and 1298 involve changes in protein sequence. The 677 SNP variant is a missense mutation in exon 4 at nucleotide 677, in which cytosine (frequent allele) is substituted by thymine, which converts an alanine to a valine codon. 26 The 1298 SNP variant corresponds to an adenosine (frequent allele) to cytosine transversion at nucleotide 1298, in exon 7, leading to a glutamate to alanine substitution. 27 Thus, the combination of two alleles per SNP in two SNPs yields four possible haplotypes leading to four protein variants. In our haplotype analysis, we found these SNPs to be fully linked (D 0 value for linkage disequilibrium ¼ 0.999), the double mutant 677T1298C (TC) being a very infrequent haplotype, as described previously. 25 Therefore, in fact only three haplotypes (corresponding to three protein variants) are abundant enough to be considered as present in the population: wild type 677C1298A (CA), and the two single mutations 677T1298A (TA) and 677C1298C (CC). Thus, in the absence of the double mutant, C677T transition is equivalent to the T677A1298 haplotype, while A1298C is equivalent to the C677C11298 haplotype. Mutant variants have decreased enzyme activity with respect to the CA wild-type haplotype, the values being 45% for TA and 68% for CC. 28 Such variants are different not only in terms of enzyme activity. For example, the 677T allele (TA haplotype) is a thermolabile variant and a genetic determinant of hyperhomocysteinemia. 26 This association with homocysteine levels is contingent on folate status. 29 The protective effect of folate may be mediated by stabilization of flavine-adenine dinucleotide binding. 29 On the other hand, the 1298C allele (CC haplotype) does not present thermolability, 27 and has no effect on homocysteine levels. 30 
Interaction of MTHFR haplotypes with chemotherapeutic drugs
Such differences have metabolic consequences when interacting with chemotherapeutic drugs that interfere with MTHFR related pathways. For example, the MTHFR 677T allele (TA haplotype) increases chemosensitivity of colon and breast cancer cells to 5-FU, but decreases chemosensitivity of breast cancer cells to methotrexate, 31 compared with the wild-type allele. On the other hand, several studies in advanced colorectal 18, 32 and breast cancer 33 have found that patient response to 5-FU is significantly linked to C677T SNP, patients with the 677T allele (TA haplotype) being more sensitive to 5-FU than those with the wild-type 677C (CA or CC haplotype), but not related to the A1298C genotype. In theory, the fact that a MTHFR protein variant with lower activity exhibits greater sensitivity to 5-FU, could be explained because lesser MTHFR activity would result in an increase in the 5,10-methylene tetrahydrofolate amount directed towards DNA synthesis.
Consequently, incorporation of 5 0 -FU nucleotides to DNA would be favored, which would increase the inhibitory effect on DNA synthesis and repair. 34, 35 On the other hand, the relationship between the MTHFR haplotype and methotrexate remains controversial. Some authors report a relationship between TA haplotype (677T) and methotrexate sensitivity 36 or toxicity, 37 while others have found no association to sensitivity 31, 38 or toxicity. 38, 39 Little is known about the interaction of MTHFR haplotypes with other drugs that can interact with its route, such as cytarabine, or with combinations of several of these drugs.
Taking into account these previous findings, we have attempted to find some evidence to explain why MTHFR t-MDS/AML risk haplotypes were different in breast cancer and hematological malignancies. We first examined aspects in breast cancer treatments that were not present in hematological treatments, and vice versa, which could be related to MTHFR activity. Thus, we considered that most non-ASCT hematological patients received alkylating agents (mainly cyclophosphamide) and topoisomerase II inhibitors (etoposides and/or antibiotics). Most of them received vinca alkaloids and antimetabolites (such as cytarabine, fludarabine, methotrexate and carbazine), but they did not receive 5-FU in any case (see Table 3 for details). Most breast cancer patients also received alkylating cyclophosphamide and topoisomerase II inhibitors (antibiotics only), and methotrexate (though to a lesser extent). However, most of them did receive 5-FU. Thus, we speculate on the possibility that the interaction of 5-FU and the TA haplotype, in the presence of cyclophosphamide-antibiotic exposure, was related to genetic predisposition to t-MDS/AML in breast cancer patients. We performed haplotype analysis in the global breast cancer population, and in those patients who 5-FU. We found an association of the TA haplotype to t-MDS/AML risk after breast cancer in both cases.
How could MTHFR haplotype influence the risk of secondary leukemia after 5-FU? The Genatlas expression profile of MTHFR shows that this gene is highly expressed in bone marrow, lymph nodes and spleen. Thus, it seems that MTHFR function is very important in hematopoietic cell metabolism. On the other hand, it is known that the incorporation of the 5-FU metabolite, FdUMP, instead of dump, into DNA results in the inhibition of DNA synthesis and repair. If the TA haplotype results in a less active protein than the CC and CA variants, then the amount of 5,10-methylene tetrahydrofolate directed towards DNA synthesis would increase, and thus the incorporation of 5 0 -FU nucleotides to DNA would be favored. Hence, the inhibitory effect on DNA synthesis and repair increases, as does the risk of chromosomal aberrations in hematopoietic cells. For this reason, the risk of developing a secondary leukemia should be higher in breast cancer patients treated with 5-FU who preferentially show the TA haplotype. In fact, only one breast cancer patient with t-MDS/AML did not have at least one copy of the TA haplotype in the MTHFR gene. All the others had one or two copies of TA. On the other hand, in the control group, 50% of the patients (nine of 18) had no copy of TA. Thus, it seems that the combination of 5-FU and the TA haplotype could be strongly related to genetic predisposition to t-MDS/AML in breast cancer patients. We do not claim that the combination of 5-FU with the MTHFR TA haplotype intrinsically predisposes to t-MDS/AML, although when patients receive DNA damaging agents such as alkylating drugs and/or topoisomerase II inhibitors in combination with 5-FU, the TA haplotype can be a risk factor for the development of t-MDS/AML. Unfortunately, we cannot evaluate 5-FU and cyclophosphamide influence separately, because all of the patients who received 5-FU received cyclophosphamide as well; thus, a synergistic effect can only be inferred.
In addition, we found a strong association between the CC haplotype and the risk of t-MDS/AML in the non-transplanted hematological malignancy population, particularly in those patients who received cyclophosphamide-based schemes. The explanation as to why the CC (and not the TA) haplotype is related to leukemia risk after treatment in hematological patients is not clear. The absence of 5-FU in hematological treatments can explain why TA is not related to such an association, but it does not explain the relevance of the CC haplotype. We suggest that such differences could be related to differences in chemotherapy schemes between hematological and breast cancer patients, and their differential interaction with MTHFR pathways. Hematological patients (but not breast cancer patients) received Cytarabine and Vinca alkaloids. Cytarabine metabolization gives as result ara-UMP 40 that could be directed toward MTHFR route. Vinca alkaloids could increase MTHFR expression through activation of NF-kappa B. 41, 42 Such interactions could play a role on t-MDS/AML risk associated with MTHFR haplotype. In any case, the CC haplotype relation to t-MDS/AML risk could be related in some way to an increased inhibition of DNA repair, required to restore alkylating drug and/or topoisomerase II inhibitor-mediated DNA damage.
Conclusion
We found a strong association between MTHFR haplotype (SNPs in positions 677 and 1298) and the risk of developing t-MDS/AML after breast cancer and hematological malignancies in populations receiving cyclophosphamide-based schemes. This association is sufficiently significant to be found in such small size populations. The risk haplotype was different for each case, the mutant variant in position 677 (TA haplotype) being the risk haplotype after breast cancer treatment, while the mutant variant in position 1298 (CC haplotype) was the risk haplotype after the treatment of hematological malignancy. We postulate that such differences in risk haplotype are related to variations in chemotherapy schemes between breast cancer and hematological patients, and their differential interaction with the MTHFR pathwayFthough we have no evidence on the mechanism of action that could explain such a strong association. We suggest that MTHFR haplotype could be related to t-MDS/AML probably because DNA repair is impaired, in circumstances where it is strongly required to restore the important DNA damage caused by alkylating agents and/or topoisomerase II inhibitors. Inhibition of DNA repair could increase the risk of chromosomal aberrations in hematopoietic cells and, as a consequence, the risk of developing secondary leukemia. In breast cancer patients treated with 5-FU who preferentially exhibit the TA haplotype, such inhibition could be due to an increased incorporation of 5 0 -FU nucleotides to DNA due to a reduction in MTHFR enzymatic activity.
We do not rule out the possibility that other SNPs may be related to t-MDS/AML, though a larger population with homogeneous treatments must be analyzed to find genetic influences, which could be less significant.
